Champions Oncology, Inc. — FY2020 Form 10-K
Business context and reporting period. Champions develops and sells oncology drug-development services using its TumorGraft patient-derived xenograft platform. Its primary business is Translational Oncology Solutions (TOS), serving pharmaceutical and biotechnology customers; Personalized Oncology Solutions (POS), serving physicians and patients, is being phased out as a growth focus. The audited reporting period is the fiscal year ended April 30, 2020, compared with fiscal 2019; this is not a calendar-year or standalone “2019 Q4” report.
Key financial results
| Metric | FY2020 | FY2019 |
|---|---|---|
| Oncology services revenue | $32.1 million | $27.1 million |
| Operating income (loss) | $(1.8) million | $0.27 million |
| Net income (loss) | $(2.0) million | $0.13 million |
| Gross margin | 47.4% | 47.3% |
| Cash provided by operating activities | $2.9 million | $1.9 million |
| Cash used in investing activities | $(2.2) million | $(0.8) million |
| Cash provided by financing activities | $4.4 million | $1.2 million |
- Revenue increased 18.7%, driven by more and larger studies, demand growth, platform expansion, and more complex study designs. Pharmacology services revenue was $31.3 million, up from $25.5 million; POS revenue fell 38.1% to $790,000 from $1.3 million.
- Gross profit was approximately $15.2 million. Operating expenses rose 26.6% to $33.9 million, faster than revenue, including higher R&D, sales and marketing, and general and administrative spending. The company recorded a $335,000 goodwill impairment for POS.
- At April 30, 2020, cash was $8.3 million, working capital was $1.4 million, and accumulated deficit was $72.7 million. Current assets were $13.5 million and current liabilities $12.1 million.
- Total liabilities were $15.4 million, including $3.7 million of operating lease liabilities and $125,000 of current finance lease liabilities. The filing reports no off-balance-sheet debt or similar obligations. The balance sheet also includes $5.8 million of deferred revenue.
- Operating cash flow exceeded net income despite the net loss; cash generation included increases in accrued liabilities and deferred revenue. Investing outflows primarily funded laboratory equipment. Financing inflows chiefly reflected option and warrant exercises, including $4.455 million in proceeds.
Material changes and outlook
- Management said available cash, together with continued improvement in operating cash flows, should fund operations through at least August 2021; it cautioned that additional capital might be needed and could not be assured on acceptable terms.
- The company plans to prioritize TOS, expand the TumorBank, develop new offerings including humanized-immune-system ImmunoGrafts, and pursue larger studies. It provided no quantified revenue, earnings, or cash-flow guidance.
- R&D spending increased 22.0% to $5.9 million. Sales and marketing expense increased 38.8% to $4.2 million, and G&A increased 41.4% to $6.6 million; management attributed these increases primarily to compensation, sales-force expansion, and a CEO bonus.
- Operating lease accounting was adopted in FY2020, bringing lease assets and liabilities onto the balance sheet. A laboratory expansion lease beginning June 1, 2020 is expected to add approximately $3.8 million each in right-of-use assets and lease liabilities. A separate facility lease was terminated June 30, 2020; the company expected a $76,000 gain on termination.
- COVID-19 had not materially affected operations or workforce as of the July 2020 filing, and management then did not expect a material long-term impact. It nevertheless identified possible disruption to travel, partnerships, biological shipments, suppliers, and customer interactions.
- Key risks include ongoing losses and funding needs, customer cancellation or modification of studies, competition, dependence on key staff and laboratory/mouse operations, regulatory uncertainty around laboratory-developed tests, and the platform’s lack of patent protection. POS services currently lack third-party reimbursement. The company also disclosed possible Section 382 limits on tax attributes and a full valuation allowance against deferred tax assets.
Important facts for investors to verify
- Whether TOS revenue growth and bookings continue, and whether study growth converts into sustained profitability and operating cash flow.
- How cash burn, working capital, and the August 2021 funding estimate evolve, especially after laboratory expansion commitments.
- Whether gross margins remain stable as study volume, outsourced laboratory services, and new product development change.
- The financial and operational effects of phasing out POS, including future impairment or restructuring charges.
- Actual COVID-19 effects on customers, supply chains, research operations, and study schedules beyond management’s assessment at filing.
- Potential dilution from equity awards or future financing: shares outstanding increased to 12.7 million at year-end, and 2.27 million stock options remained outstanding; all warrants had been exercised, forfeited, or expired by April 30, 2020.